Clinical trials: Acute Myelogenous Leukemia AML
Acute Myeloid Leukemia
Epidemiology of Infection in Acute Myeloid Leukemia (AML)
In recent years, multiple factors have strongly impacted the epidemiology of infections in patients with acute myeloid leukemia. On the one hand, the availability of new effective antileukemic drugs (i.e.
- Trial name
- EPIAMLINF (NCT06797648)
- Testing
- data analysis
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Relapsed/Refractory Acute Myeloid Leukemia(AML)
A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia
A Clinical Study to Investigate the Safety and Efficacy of CT0991 in Patients with Relapsed/Refractory Acute Myeloid Leukemia.
- Trial name
- NCT07233018
- Testing
- CT0991 CAR-T cells infusicn
- Where
- China
- Volunteers
- 24 people
- Sponsor
- MEI HENG
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML
The proposed study is designed to combine crenolanib with standard salvage chemotherapy to treat patients with R/R AML irrespective the FLT3 status.
- Trial name
- NCT02626338
- Testing
- Crenolanib, Mitoxantrone, Cytarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Leukemia, Myeloid
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Open-label, non-randomized, parallel assignment, phase 2 trial assessing the safety and efficacy of distinct temozolomide treatment regimens for patients with AML and poor prognosis
- Trial name
- NCT00611247
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Bruno C. Medeiros
Hematological Malignancies
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogneic signal is present.
- Trial name
- NCT00438178
- Testing
- Obatoclax mesylate (GX15-070MS)
- Where
- 3 sites in United States, Canada
- Volunteers
- 44 people
- Sponsor
- Gemin X
High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML)
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS, CMML, and CML. Participants aged ≥ 12 years are planned to be enrolled.
- Conditions
- High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
- Trial name
- CROSSCHECK-001 (NCT06994676)
- Testing
- CBX-250
- Where
- 11 sites in United States
- Volunteers
- 72 people
- Sponsor
- Crossbow Therapeutics, Inc.
Anemia, Leukemia
Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Colony-stimulating factors such as leridistim and filgrastim increase the number of immune cells found in…
- Conditions
- Anemia, Leukemia, Neutropenia, Thrombocytopenia
- Trial name
- NCT00004215
- Testing
- filgrastim, leridistim, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Leukemia (Both ALL and AML), MDS-EB-1
Ikervis for DED Due to GVHD Post Allo-HSCT
Dry eye disease (DED) is a common sequelae of graft versus host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Trial name
- Ikervis (NCT04636918)
- Testing
- Cyclosporine Ophthalmic
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- Singapore Eye Research Institute
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Observational Study of Iron Overload in Stem Cell Transplantation
Recent retrospective studies have suggested that iron overload is a clinically important problem in patients undergoing ablative stem cell transplantation.
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00954720
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
AML, Childhood
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pediatric patients (<21 years at study entry) with relapsed or refractory acute myeloid leukemia (AML) will be treated with CD33*CD3 a bispecific antibody to investigate the safety and tolerability of the drug.
- Trial name
- NCT05077423
- Testing
- CD33*CD3 BsAb
- Where
- 13 sites in United States
- Volunteers
- 3 people
- Sponsor
- Y-mAbs Therapeutics
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of abnormal and cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00346359
- Testing
- anti-thymocyte globulin, busulfan, fludarabine phosphate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
The goal of this clinical research study is to learn if the combination of clofarabine, cytarabine, and idarubicin can help to control Acute Myeloid Leukemia (AML) in patients who are between the ages of 18 and 60 years old.
- Trial name
- NCT01025154
- Testing
- Clofarabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia, Relapsed Cancer
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
The purpose of this research study is to see how safe and tolerable, and to find the highest or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in patients with relapsed (the cancer has…
- Conditions
- Acute Myeloid Leukemia, Relapsed Cancer, Refractory Cancer, IDH2 Gene Mutation
- Trial name
- NCT04092179
- Testing
- Enasidenib, Venetoclax
- Where
- 2 sites in Canada
- Volunteers
- 27 people
- Sponsor
- University Health Network, Toronto
Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL)
Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment
To assess the impact of moderate hepatic impairment on cytarabine and daunorubicin pharmacokinetics and their metabolites following administration of CPX-351.
- Conditions
- Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT02269579
- Testing
- CPX-351
- Where
- 5 sites in United States
- Sponsor
- Jazz Pharmaceuticals
Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer
A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. This study focuses on two types of cancers: Acute Myeloid Leukemia (AML) and Non-Small Cell Lung Cancer (NSCLC).
- Conditions
- Acute Myeloid Leukemia (AML), Non Small Cell Lung Cancer, Cancer
- Trial name
- NCT04272203
- Testing
- ABBV-184
- Where
- 17 sites in United States, France and 3 more
- Volunteers
- 14 people
- Sponsor
- AbbVie
Acute Myeloid Leukemia
Hematopoietic Stem Cell Microtransplantation for in AML
The purpose of this study is to evaluate the efficacy of hematopoietic stem cell microtransplantation for in acute myeloid leukemia (AML)patients who can not receive hematopoietic stem cell transplantation (HSCT).
- Trial name
- NCT02676856
- Testing
- hematopoietic stem cell microtransplantation-long-term, hematopoietic stem cell microtransplantation-short-term, Conditioning for CR group
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndromes (MDS)
A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes
Study Objectives: To collect and describe demographics, disease-management, and treatment outcomes of Myelodysplastic Syndromes (MDS) patients who are newly diagnosed and classified according to the World Health Organization…
- Trial name
- EUMDS (NCT00600860)
- Testing
- No interventions
- Where
- 18 sites in Austria, Croatia and 16 more
- Volunteers
- 4,000 people
- Sponsor
- Radboud University Medical Center
Myelodysplastic Syndrome, Acute Myelogenous Leukemia
A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
In this study, MGCD0103, a new anticancer drug under investigation, is given three times weekly in combination with azacitidine to patients with high-risk myelodysplastic syndromes or acute myelogenous leukemia.
- Trial name
- NCT00324220
- Testing
- MGCD0103
- Where
- 8 sites in United States
- Volunteers
- 66 people
- Sponsor
- Mirati Therapeutics Inc.
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Haploidentical Stem Cell Transplantation With CD3/CD19 Depletion and Reduced Intensity Conditioning in Patients With Acute Leukemia
Feasibility and toxicity of haploidentical allogeneic HCT after a reduced intensity conditioning regimen with CD3/CD19 depleted grafts.
- Trial name
- CD3/CD19 Haplo (NCT00961142)
- Testing
- Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)
- Where
- 8 sites in Germany
- Volunteers
- 23 people
- Sponsor
- University Hospital Tuebingen
Bortezomib, Acute Myeloid Leukemia
Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML
In recent years, the efficacy of AML has been greatly improved, which is mainly due to the following aspects: the development of individualized treatment strategies based on genetic prognosis stratification, the application of…
- Trial name
- NCT05982756
- Testing
- DAG pre-excitation regimen with Bortezomib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhongnan Hospital